Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;41(3):301-309.
doi: 10.1002/hon.3088. Epub 2022 Oct 25.

Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy

Han-Yu Cao  1 , Ling Li  2 , Sheng-Li Xue  1 , Hai-Ping Dai  1
Affiliations
Review

Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy

Han-Yu Cao et al. Hematol Oncol. 2023 Aug.

Abstract

Epigenetic alterations frequently participate in the onset of hematological malignancies. Histone deacetylases (HDACs) are essential for regulating gene transcription and various signaling pathways. Targeting HDACs has become a novel treatment option for hematological malignancies. Chidamide is the first oral selective HDAC inhibitor for HDAC1, HDAC2, HDAC3, and HDAC10 and was first approved for the treatment of R/R peripheral T-cell lymphoma by the China Food and Drug Administration in 2014. Chidamide was also approved under the name Hiyasta (HBI-8000) in Japan in 2021. In vitro studies revealed that chidamide could inhibit proliferation and induce apoptosis via cell cycle arrest and the regulation of apoptotic proteins. In clinical studies, chidamide was also efficacious in multiple myeloma, acute leukemia and myelodysplastic syndrome. This review includes reported experimental and clinical data on chidamide monotherapy or chidamide treatment in combination with chemotherapy for various hematological malignancies, offering a rationale for the renewed exploration of this drug.

Keywords: HDAC inhibitors; chidamide; hematological malignancy; mechanism.

PubMed Disclaimer

References

REFERENCES

    1. Bonasio R, Tu S, Reinberg D. Molecular signals of epigenetic states. Science. 2010;330(6004):612-616. https://doi.org/10.1126/science.1191078
    1. Richter LE, Wang Y, Becker ME, et al. HDAC1 is a required cofactor of CBFβ-SMMHC and a potential therapeutic target in inversion 16 acute myeloid leukemia. Mol Cancer Res. 2019;17(6):1241-1252. https://doi.org/10.1158/1541-7786.Mcr-18-0922
    1. Ferrante F, Giaimo BD, Bartkuhn M, et al. HDAC3 functions as a positive regulator in Notch signal transduction. Nucleic Acids Res. 2020;48(7):3496-3512. https://doi.org/10.1093/nar/gkaa088
    1. Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766-1771. https://doi.org/10.1093/annonc/mdv237
    1. Gong K, Xie J, Yi H, Li W. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J. 2012;443(3):735-746. https://doi.org/10.1042/bj20111685

Substances

LinkOut - more resources